Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.
Also called NCT06601127
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 600 participants
- Sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
- Registry
-
NCT06601127
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06601127. Randomized; quadruple masking; primary purpose treatment. Start 2025-02-21 (actual); primary completion 2026-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Tiprogrel
- Intervention (Drug)
- Tiprogrel
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
Record details
- Record id
cardio:ct-nct06601127- Content hash
6c35edfac0ecab014102a9c8954fc0b78c8ad9dbfbdbd19f5b2447c79e41f1b8